Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes

Summary

The purpose of this pilot study is that exosomes constitute a more interesting support for analyzes allowing a broader screening of molecular alterations to be carried out with more reliable, more sensitive and more efficient results than the reference Foundation One Liquid CDx test.

Eligibility

Inclusion Criteria:

* Subject of both sexes at least 18 years of age with glioblastoma.
* Patient for whom an FMI test is indicated, progressing after a 1st line following the chemotherapy and radiotherapy protocol (STUPP protocol)
* Patient affiliated to French social security

Exclusion Criteria:

* Patient included in another research protocol using an experimental molecule.
* Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the patient from adhering to the protocol or completing the study per protocol
* Patient under legal protection, guardianship or curatorship
* Patient with active malignancy or a previous malignancy within the past 5 years; except for patient with resected Basocarcinoma and resected carcinoma in-situ of the cervix.

Conditions2

Browse More Trials